Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARYA Sciences Acquisition Corp VARYE · Entity 137308 | Chief Business Officer | July 12, 2021 | July 12, 2021 |
| Cerevel Therapeutics Holdings, Inc.ARYB · Entity 15182 | Chief Business Officer | June 04, 2020 | June 04, 2020 |
| Kadmon Holdings, Inc.KDMN · Entity 133686 | Executive Vice President, CFO | December 08, 2017 | December 12, 2017 |
| Landos Biopharma, Inc.LABP · Entity 90644 | Director · 10% owner | February 05, 2021 | February 09, 2021 |
| LianBioLIAN · Entity 9881 | Director | February 15, 2024 | February 20, 2024 |
| Lyra Therapeutics, Inc.LYRA · Entity 46837 | Director | June 13, 2024 | June 14, 2024 |
| Nautilus Biotechnology, Inc.ARYA · Entity 6679 | Chief Business Officer | August 06, 2020 | August 07, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARYA Sciences Acquisition Corp V
Report date July 12, 2021 · Filed July 12, 2021
This filing explicitly reported no securities owned.
Cerevel Therapeutics Holdings, Inc.
Report date June 04, 2020 · Filed June 04, 2020
This filing explicitly reported no securities owned.
Kadmon Holdings, Inc.
Report date December 08, 2017 · Filed December 12, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Appreciation RightSEC Table II · derivative / convertible security · Conversion / exercise price $3.64 · Expires 2027-12-08 | Direct | 205,000 |
Reported balance
After 2017-12-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-12-08 · Grant · Acquired 205,000 · Balance 205,000 F1: The stock appreciation right vests and becomes exercisable in three equal annual installments over 3 years from December 8, 2017, the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock appreciation right vests and becomes exercisable in three equal annual installments over 3 years from December 8, 2017, the date of grant.
Landos Biopharma, Inc.
Report date February 05, 2021 · Filed February 09, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy funds | 14,869,915 |
Last balance in matching sequence
After 2021-02-09 transaction · row 6
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
6 source rowsRow 1 · 2021-02-05 · Purchase · Acquired 27,453 · Balance 14,647,181 F1: The prices reported in Column 4 are weighted average prices. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges of the prices reported on this Form 4. F2: These shares were purchased in multiple transactions at prices ranging from $11.05 to $11.75, inclusive. F3: Securities are held by Perceptive Life Sciences Master Fund, Ltd. ("PLSMF"), Perceptive Xontogeny Venture Fund, LP ("PXVF"), and PX Venture (A), LLC ("PXV"). Perceptive Advisors, LLC ("Perceptive Advisors") serves as the investment manager to PLSMF, PXVF, and PXV. The Reporting Person is a managing director of Perceptive Advisors. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Row 2 · 2021-02-08 · Purchase · Acquired 34,611 · Balance 14,681,792 F1: The prices reported in Column 4 are weighted average prices. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges of the prices reported on this Form 4. F4: These shares were purchased in multiple transactions at prices ranging from $10.96 to $11.93, inclusive. F3: Securities are held by Perceptive Life Sciences Master Fund, Ltd. ("PLSMF"), Perceptive Xontogeny Venture Fund, LP ("PXVF"), and PX Venture (A), LLC ("PXV"). Perceptive Advisors, LLC ("Perceptive Advisors") serves as the investment manager to PLSMF, PXVF, and PXV. The Reporting Person is a managing director of Perceptive Advisors. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Row 3 · 2021-02-08 · Purchase · Acquired 86,671 · Balance 14,768,463 F1: The prices reported in Column 4 are weighted average prices. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges of the prices reported on this Form 4. F5: These shares were purchased in multiple transactions at prices ranging from $11.96 to $12.95, inclusive. F3: Securities are held by Perceptive Life Sciences Master Fund, Ltd. ("PLSMF"), Perceptive Xontogeny Venture Fund, LP ("PXVF"), and PX Venture (A), LLC ("PXV"). Perceptive Advisors, LLC ("Perceptive Advisors") serves as the investment manager to PLSMF, PXVF, and PXV. The Reporting Person is a managing director of Perceptive Advisors. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Row 4 · 2021-02-08 · Purchase · Acquired 1,771 · Balance 14,770,234 F1: The prices reported in Column 4 are weighted average prices. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges of the prices reported on this Form 4. F6: These shares were purchased in multiple transactions at prices ranging from $13.09 to $13.10, inclusive. F3: Securities are held by Perceptive Life Sciences Master Fund, Ltd. ("PLSMF"), Perceptive Xontogeny Venture Fund, LP ("PXVF"), and PX Venture (A), LLC ("PXV"). Perceptive Advisors, LLC ("Perceptive Advisors") serves as the investment manager to PLSMF, PXVF, and PXV. The Reporting Person is a managing director of Perceptive Advisors. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Row 5 · 2021-02-09 · Purchase · Acquired 64,730 · Balance 14,834,964 F1: The prices reported in Column 4 are weighted average prices. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges of the prices reported on this Form 4. F7: These shares were purchased in multiple transactions at prices ranging from $13.17 to $14.16, inclusive. F3: Securities are held by Perceptive Life Sciences Master Fund, Ltd. ("PLSMF"), Perceptive Xontogeny Venture Fund, LP ("PXVF"), and PX Venture (A), LLC ("PXV"). Perceptive Advisors, LLC ("Perceptive Advisors") serves as the investment manager to PLSMF, PXVF, and PXV. The Reporting Person is a managing director of Perceptive Advisors. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Row 6 · 2021-02-09 · Purchase · Acquired 34,951 · Balance 14,869,915 F1: The prices reported in Column 4 are weighted average prices. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges of the prices reported on this Form 4. F8: These shares were purchased in multiple transactions at prices ranging from $14.17 to $15.20, inclusive. F3: Securities are held by Perceptive Life Sciences Master Fund, Ltd. ("PLSMF"), Perceptive Xontogeny Venture Fund, LP ("PXVF"), and PX Venture (A), LLC ("PXV"). Perceptive Advisors, LLC ("Perceptive Advisors") serves as the investment manager to PLSMF, PXVF, and PXV. The Reporting Person is a managing director of Perceptive Advisors. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The prices reported in Column 4 are weighted average prices. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges of the prices reported on this Form 4.
F2: These shares were purchased in multiple transactions at prices ranging from $11.05 to $11.75, inclusive.
F3: Securities are held by Perceptive Life Sciences Master Fund, Ltd. ("PLSMF"), Perceptive Xontogeny Venture Fund, LP ("PXVF"), and PX Venture (A), LLC ("PXV"). Perceptive Advisors, LLC ("Perceptive Advisors") serves as the investment manager to PLSMF, PXVF, and PXV. The Reporting Person is a managing director of Perceptive Advisors. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
F4: These shares were purchased in multiple transactions at prices ranging from $10.96 to $11.93, inclusive.
F5: These shares were purchased in multiple transactions at prices ranging from $11.96 to $12.95, inclusive.
F6: These shares were purchased in multiple transactions at prices ranging from $13.09 to $13.10, inclusive.
F7: These shares were purchased in multiple transactions at prices ranging from $13.17 to $14.16, inclusive.
F8: These shares were purchased in multiple transactions at prices ranging from $14.17 to $15.20, inclusive.
LianBio
Report date February 15, 2024 · Filed February 20, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 17,082 |
Ending reported balance
After 2024-02-15 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-02-15 · Exercise / conversion · Acquired 36,300 · Balance 36,300 Row 2 · 2024-02-15 · Tax withholding · Disposed 19,218 · Balance 17,082 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.52 · Expires 2032-06-23 | Direct | 0 |
Reported balance
After 2024-02-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-02-15 · Exercise / conversion · Disposed 36,300 · Balance 0 |
Lyra Therapeutics, Inc.
Report date June 13, 2024 · Filed June 14, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.31 · Expires 2034-06-12 | Direct | 30,000 |
Reported balance
After 2024-06-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-13 · Grant · Acquired 30,000 · Balance 30,000 F1: This option vests and becomes exercisable on the earlier of (i) June 13, 2025 (the one-year anniversary of the date of grant) and (ii) the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case, subject to the Non-Employee Director's continued service on the Board as a Non-Employee Director through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests and becomes exercisable on the earlier of (i) June 13, 2025 (the one-year anniversary of the date of grant) and (ii) the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case, subject to the Non-Employee Director's continued service on the Board as a Non-Employee Director through such vesting date.
Nautilus Biotechnology, Inc.
Report date August 06, 2020 · Filed August 07, 2020
This filing explicitly reported no securities owned.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ARYA Sciences Acquisition Corp IV
Report date July 31, 2024 · Filed July 31, 2024
Section 16 reporting ended · disclosed 2024-07-31. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 13, 2024 Filed Jun 14, 2024 20:10 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | GrantStock Option · Derivative | 30,000 | $0.00 Strike: $0.31 | $0.00 |
DisclosureSEC source: 0000950170-24-073650 · ownership.xml · derivative · entry 1 Poukalov Konstantin · CIK 0001678736 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2034-06-12 F1 · derivative.exercise_date: This option vests and becomes exercisable on the earlier of (i) June 13, 2025 (the one-year anniversary of the date of grant) and (ii) the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case, subject to the Non-Employee Director's continued service on the Board as a Non-Employee Director through such vesting date. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 22:27 UTC | LianBio LIAN · Entity 9881 | Exercise / conversionStock Option (Right to Buy) · Derivative | 36,300 | $0.00 Strike: $2.52 | $0.00 |
DisclosureSEC source: 0001062993-24-003733 · form4.xml · derivative · entry 3 Poukalov Konstantin · CIK 0001678736 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 36,300 shares Expires 2032-06-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 22:27 UTC | LianBio LIAN · Entity 9881 | Tax withholdingOrdinary Shares | 19,218 | $4.76 | $91,477.68 |
DisclosureSEC source: 0001062993-24-003733 · form4.xml · nonDerivative · entry 2 Poukalov Konstantin · CIK 0001678736 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,082 Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 22:27 UTC | LianBio LIAN · Entity 9881 | Exercise / conversionOrdinary Shares | 36,300 | $2.52 | $91,476.00 |
DisclosureSEC source: 0001062993-24-003733 · form4.xml · nonDerivative · entry 1 Poukalov Konstantin · CIK 0001678736 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 30, 2023 Filed Jul 6, 2023 01:50 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $4.11 | $0.00 |
DisclosureSEC source: 0000950170-23-031869 · ownership.xml · derivative · entry 1 Poukalov Konstantin · CIK 0001678736 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-06-29 F1 · derivative.exercise_date: This option vests and becomes exercisable on June 30, 2024, subject to the Non-Employee Director's continued service on the Board as a Non-Employee Director through such vesting date. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 20:10 UTC | LianBio LIAN · Entity 9881 | GrantStock Option (Right to Buy) · Derivative | 36,300 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001062993-23-013980 · form4.xml · derivative · entry 1 Poukalov Konstantin · CIK 0001678736 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,300 Underlying: Ordinary Shares · 36,300 shares Expires 2033-06-21 F1 · derivative.exercise_date: The shares underlying the option shall vest and become exercisable in full on June 21, 2024, the first anniversary of the grant date, subject to the Reporting Person providing continuous service to the Issuer through such date. Read SEC document |
| June 23, 2022 Filed Jun 27, 2022 21:37 UTC | LianBio LIAN · Entity 9881 | GrantStock Option (Right to Buy) · Derivative | 36,300 | $0.00 Strike: $2.52 | $0.00 |
DisclosureSEC source: 0001062993-22-015490 · form4.xml · derivative · entry 1 Poukalov Konstantin · CIK 0001678736 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,300 Underlying: Ordinary Shares · 36,300 shares Expires 2032-06-23 F1 · derivative.exercise_date: The shares underlying the option shall vest and become exercisable in full on June 23, 2023, the first anniversary of the grant date, subject to the Reporting Person providing continuous service to the Issuer through such date. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 20:06 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | GrantStock Option · Derivative | 7,250 | $0.00 Strike: $5.09 | $0.00 |
DisclosureSEC source: 0000899243-22-023337 · doc4.xml · derivative · entry 1 Poukalov Konstantin · CIK 0001678736 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,250 Underlying: Common Stock · 7,250 shares Expires 2032-06-15 F1 · derivative.exercise_date: This option vests and becomes exercisable on the earlier of (i) June 16, 2023 (the one-year anniversary of the date of grant) and (ii) the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Non-Employee Director's continued service on the Board as a Non-Employee Director through such vesting date. Read SEC document |
| May 26, 2021 Filed May 28, 2021 22:25 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | GrantStock Option · Derivative | 7,250 | $0.00 Strike: $7.24 | $0.00 |
DisclosureSEC source: 0000899243-21-021189 · doc4.xml · derivative · entry 1 Poukalov Konstantin · CIK 0001678736 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,250 Underlying: Common Stock · 7,250 shares Expires 2031-05-25 F1 · derivative.exercise_date: This option vests and becomes exercisable on the earlier of (i) May 26, 2022 (the one-year anniversary of the date of grant) and (ii) the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Non-Employee Director's continued service on the Board as a Non-Employee Director through such vesting date. Read SEC document |
| February 09, 2021 Filed Feb 9, 2021 19:56 UTC | Landos Biopharma, Inc. LABP · Entity 90644 | PurchaseCommon Stock | 34,951 | $14.60 | $510,284.60 |
DisclosureSEC source: 0001209191-21-009047 · doc4.xml · nonDerivative · entry 6 Poukalov Konstantin · CIK 0001678736 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By funds Disclosed balance after: 14,869,915 F1 · price: The prices reported in Column 4 are weighted average prices. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges of the prices reported on this Form 4. F8 · price: These shares were purchased in multiple transactions at prices ranging from $14.17 to $15.20, inclusive. F3 · ownership.nature: Securities are held by Perceptive Life Sciences Master Fund, Ltd. ("PLSMF"), Perceptive Xontogeny Venture Fund, LP ("PXVF"), and PX Venture (A), LLC ("PXV"). Perceptive Advisors, LLC ("Perceptive Advisors") serves as the investment manager to PLSMF, PXVF, and PXV. The Reporting Person is a managing director of Perceptive Advisors. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 09, 2021 Filed Feb 9, 2021 19:56 UTC | Landos Biopharma, Inc. LABP · Entity 90644 | PurchaseCommon Stock | 64,730 | $13.80 | $893,274.00 |
DisclosureSEC source: 0001209191-21-009047 · doc4.xml · nonDerivative · entry 5 Poukalov Konstantin · CIK 0001678736 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By funds Disclosed balance after: 14,834,964 F1 · price: The prices reported in Column 4 are weighted average prices. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges of the prices reported on this Form 4. F7 · price: These shares were purchased in multiple transactions at prices ranging from $13.17 to $14.16, inclusive. F3 · ownership.nature: Securities are held by Perceptive Life Sciences Master Fund, Ltd. ("PLSMF"), Perceptive Xontogeny Venture Fund, LP ("PXVF"), and PX Venture (A), LLC ("PXV"). Perceptive Advisors, LLC ("Perceptive Advisors") serves as the investment manager to PLSMF, PXVF, and PXV. The Reporting Person is a managing director of Perceptive Advisors. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 08, 2021 Filed Feb 8, 2021 18:08 UTC | Landos Biopharma, Inc. LABP · Entity 90644 | ConversionSeries B Preferred Stock · Derivative | 7,486,190 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-008587 · doc4.xml · derivative · entry 4 Poukalov Konstantin · CIK 0001678736 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By funds Disclosed balance after: 0 Underlying: Common Stock · 7,486,190 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of the Issuer's Series B preferred stock automatically converted into 1.8249 shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series B preferred stock had no expiration date. F7 · shares: Consists of 2,857,795 shares of common stock issuable upon conversion of Series B preferred stock held by PLSMF, 2,857,795 shares of common stock issuable upon conversion of Series B preferred stock held by PXVF and 1,770,600 shares of common stock issuable upon conversion of Series B preferred stock held by PXV. Perceptive Advisors serves as the investment manager to PLSMF, PXVF, and PXV. The Reporting Person is a managing director of Perceptive Advisors. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein. F2 · price: Each share of the Issuer's Series B preferred stock automatically converted into 1.8249 shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series B preferred stock had no expiration date. F2 · derivative.exercise_date: Each share of the Issuer's Series B preferred stock automatically converted into 1.8249 shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series B preferred stock had no expiration date. F2 · derivative.expiration_date: Each share of the Issuer's Series B preferred stock automatically converted into 1.8249 shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series B preferred stock had no expiration date. F4 · ownership.nature: Securities are held by PLSMF, PXVF, and PXV. Perceptive Advisors serves as the investment manager to Perceptive PLSMF, PXVF, and PXV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a Managing Director of Perceptive Advisors and may be deemed to indirectly beneficially own the securities. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein. Read SEC document |
| February 08, 2021 Filed Feb 8, 2021 18:08 UTC | Landos Biopharma, Inc. LABP · Entity 90644 | ConversionSeries A Preferred Stock · Derivative | 5,883,538 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-008587 · doc4.xml · derivative · entry 3 Poukalov Konstantin · CIK 0001678736 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By funds Disclosed balance after: 0 Underlying: Common Stock · 5,883,538 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A preferred stock automatically converted into 1.8249 shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series A preferred stock had no expiration date. F6 · shares: Consists of 2,941,769 shares of common stock issuable upon conversion of Series A preferred stock held by PLSMF and 2,941,769 shares of common stock issuable upon conversion of Series A preferred stock held by PXVF. Perceptive Advisors serves as the investment manager to PLSMF and PXVF. The Reporting Person is a managing director of Perceptive Advisors. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. F1 · price: Each share of the Issuer's Series A preferred stock automatically converted into 1.8249 shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series A preferred stock had no expiration date. F1 · derivative.exercise_date: Each share of the Issuer's Series A preferred stock automatically converted into 1.8249 shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series A preferred stock had no expiration date. F1 · derivative.expiration_date: Each share of the Issuer's Series A preferred stock automatically converted into 1.8249 shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series A preferred stock had no expiration date. F5 · ownership.nature: Securities are held by PLSMF and PXVF. Perceptive Advisors serves as the investment manager to PLSMF and PXVF. and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a Managing Director of Perceptive Advisors and may be deemed to indirectly beneficially own the securities. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein. Read SEC document |
| February 08, 2021 Filed Feb 8, 2021 18:08 UTC | Landos Biopharma, Inc. LABP · Entity 90644 | PurchaseCommon Stock | 1,250,000 | $16.00 | $20,000,000.00 |
DisclosureSEC source: 0001209191-21-008587 · doc4.xml · nonDerivative · entry 2 Poukalov Konstantin · CIK 0001678736 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By funds Disclosed balance after: 14,619,728 F4 · ownership.nature: Securities are held by PLSMF, PXVF, and PXV. Perceptive Advisors serves as the investment manager to Perceptive PLSMF, PXVF, and PXV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a Managing Director of Perceptive Advisors and may be deemed to indirectly beneficially own the securities. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein. F5 · ownership.nature: Securities are held by PLSMF and PXVF. Perceptive Advisors serves as the investment manager to PLSMF and PXVF. and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a Managing Director of Perceptive Advisors and may be deemed to indirectly beneficially own the securities. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein. Read SEC document |
| February 08, 2021 Filed Feb 8, 2021 18:08 UTC | Landos Biopharma, Inc. LABP · Entity 90644 | ConversionCommon Stock | 13,369,728 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-008587 · doc4.xml · nonDerivative · entry 1 Poukalov Konstantin · CIK 0001678736 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By funds Disclosed balance after: 13,369,728 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the Issuer's Series A preferred stock automatically converted into 1.8249 shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series A preferred stock had no expiration date. F2 · price: Each share of the Issuer's Series B preferred stock automatically converted into 1.8249 shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series B preferred stock had no expiration date. F3 · balance_after: Consists of 5,799,564 shares of common stock held by Perceptive Life Sciences Master Fund, Ltd. ("PLSMF"), 5,799,564 shares of common stock held by Perceptive Xontogeny Venture Fund, LP ("PXVF"), and 1,770,600 shares of common stock held by PX Venture (A), LLC ("PXV"). Perceptive Advisors, LLC ("Perceptive Advisors") serves as the investment manager to PLSMF, PXVF, and PXV. The Reporting Person is a managing director of Perceptive Advisors. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. F4 · ownership.nature: Securities are held by PLSMF, PXVF, and PXV. Perceptive Advisors serves as the investment manager to Perceptive PLSMF, PXVF, and PXV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a Managing Director of Perceptive Advisors and may be deemed to indirectly beneficially own the securities. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein. F5 · ownership.nature: Securities are held by PLSMF and PXVF. Perceptive Advisors serves as the investment manager to PLSMF and PXVF. and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a Managing Director of Perceptive Advisors and may be deemed to indirectly beneficially own the securities. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein. Read SEC document |
| February 08, 2021 Filed Feb 9, 2021 19:56 UTC | Landos Biopharma, Inc. LABP · Entity 90644 | PurchaseCommon Stock | 1,771 | $13.10 | $23,200.10 |
DisclosureSEC source: 0001209191-21-009047 · doc4.xml · nonDerivative · entry 4 Poukalov Konstantin · CIK 0001678736 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By funds Disclosed balance after: 14,770,234 F1 · price: The prices reported in Column 4 are weighted average prices. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges of the prices reported on this Form 4. F6 · price: These shares were purchased in multiple transactions at prices ranging from $13.09 to $13.10, inclusive. F3 · ownership.nature: Securities are held by Perceptive Life Sciences Master Fund, Ltd. ("PLSMF"), Perceptive Xontogeny Venture Fund, LP ("PXVF"), and PX Venture (A), LLC ("PXV"). Perceptive Advisors, LLC ("Perceptive Advisors") serves as the investment manager to PLSMF, PXVF, and PXV. The Reporting Person is a managing director of Perceptive Advisors. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 08, 2021 Filed Feb 9, 2021 19:56 UTC | Landos Biopharma, Inc. LABP · Entity 90644 | PurchaseCommon Stock | 86,671 | $12.53 | $1,085,987.63 |
DisclosureSEC source: 0001209191-21-009047 · doc4.xml · nonDerivative · entry 3 Poukalov Konstantin · CIK 0001678736 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By funds Disclosed balance after: 14,768,463 F1 · price: The prices reported in Column 4 are weighted average prices. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges of the prices reported on this Form 4. F5 · price: These shares were purchased in multiple transactions at prices ranging from $11.96 to $12.95, inclusive. F3 · ownership.nature: Securities are held by Perceptive Life Sciences Master Fund, Ltd. ("PLSMF"), Perceptive Xontogeny Venture Fund, LP ("PXVF"), and PX Venture (A), LLC ("PXV"). Perceptive Advisors, LLC ("Perceptive Advisors") serves as the investment manager to PLSMF, PXVF, and PXV. The Reporting Person is a managing director of Perceptive Advisors. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 08, 2021 Filed Feb 9, 2021 19:56 UTC | Landos Biopharma, Inc. LABP · Entity 90644 | PurchaseCommon Stock | 34,611 | $11.38 | $393,873.18 |
DisclosureSEC source: 0001209191-21-009047 · doc4.xml · nonDerivative · entry 2 Poukalov Konstantin · CIK 0001678736 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By funds Disclosed balance after: 14,681,792 F1 · price: The prices reported in Column 4 are weighted average prices. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges of the prices reported on this Form 4. F4 · price: These shares were purchased in multiple transactions at prices ranging from $10.96 to $11.93, inclusive. F3 · ownership.nature: Securities are held by Perceptive Life Sciences Master Fund, Ltd. ("PLSMF"), Perceptive Xontogeny Venture Fund, LP ("PXVF"), and PX Venture (A), LLC ("PXV"). Perceptive Advisors, LLC ("Perceptive Advisors") serves as the investment manager to PLSMF, PXVF, and PXV. The Reporting Person is a managing director of Perceptive Advisors. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 19:56 UTC | Landos Biopharma, Inc. LABP · Entity 90644 | PurchaseCommon Stock | 27,453 | $11.14 | $305,826.42 |
DisclosureSEC source: 0001209191-21-009047 · doc4.xml · nonDerivative · entry 1 Poukalov Konstantin · CIK 0001678736 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By funds Disclosed balance after: 14,647,181 F1 · price: The prices reported in Column 4 are weighted average prices. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges of the prices reported on this Form 4. F2 · price: These shares were purchased in multiple transactions at prices ranging from $11.05 to $11.75, inclusive. F3 · ownership.nature: Securities are held by Perceptive Life Sciences Master Fund, Ltd. ("PLSMF"), Perceptive Xontogeny Venture Fund, LP ("PXVF"), and PX Venture (A), LLC ("PXV"). Perceptive Advisors, LLC ("Perceptive Advisors") serves as the investment manager to PLSMF, PXVF, and PXV. The Reporting Person is a managing director of Perceptive Advisors. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| April 30, 2020 Filed May 1, 2020 22:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | GrantStock Option · Derivative | 14,500 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000899243-20-011751 · doc4.xml · derivative · entry 1 Poukalov Konstantin · CIK 0001678736 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,500 Underlying: Common Stock · 14,500 shares Expires 2030-04-29 F1 · derivative.exercise_date: This option vests and becomes exercisable in 36 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following April 30, 2020. Read SEC document |
| December 08, 2017 Filed Dec 12, 2017 16:08 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | GrantStock Appreciation Right · Derivative | 205,000 | $0.00 Strike: $3.64 | $0.00 |
DisclosureSEC source: 0001593968-17-001351 · primary_01.xml · derivative · entry 1 Poukalov Konstantin · CIK 0001678736 · Executive Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,000 Underlying: Common Stock, par value $0.001 · 205,000 shares Expires 2027-12-08 F1 · derivative.exercise_date: The stock appreciation right vests and becomes exercisable in three equal annual installments over 3 years from December 8, 2017, the date of grant. Read SEC document |
| December 15, 2016 Filed Dec 16, 2016 20:22 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | GrantStock Option (right to buy) · Derivative | 350,000 | $4.66 Strike: $4.66 | $1,631,000.00 |
DisclosureSEC source: 0001593968-16-001349 · primary_01.xml · derivative · entry 1 Poukalov Konstantin · CIK 0001678736 · Executive Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock, par value $0.001 · 350,000 shares Expires 2026-12-15 F1 · derivative.exercise_date: The option becomes vested and exercisable in three equal annual installments over 3 years from December 15, 2016, the date of grant, with vesting to accelerate if employment ends for any reason other than a termination for Cause, as defined in the relevant employment agreement. F2 · balance_after: Only represents derivative securities of this class. Read SEC document |
| November 11, 2016 Filed Nov 14, 2016 08:41 UTC | Kadmon Holdings, Inc. kdmn · Entity 133686 | PurchaseCommon stock, par value $0.001 | 1,000 | $5.43 | $5,430.00 |
DisclosureSEC source: 0001557142-16-000040 · primary_doc.xml · nonDerivative · entry 4 Poukalov Konstantin · CIK 0001678736 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Read SEC document |
| November 11, 2016 Filed Nov 14, 2016 08:41 UTC | Kadmon Holdings, Inc. kdmn · Entity 133686 | PurchaseCommon stock, par value $0.001 | 1,000 | $5.95 | $5,950.00 |
DisclosureSEC source: 0001557142-16-000040 · primary_doc.xml · nonDerivative · entry 3 Poukalov Konstantin · CIK 0001678736 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Read SEC document |
| November 11, 2016 Filed Nov 14, 2016 08:41 UTC | Kadmon Holdings, Inc. kdmn · Entity 133686 | PurchaseCommon stock, par value $0.001 | 1,000 | $5.91 | $5,910.00 |
DisclosureSEC source: 0001557142-16-000040 · primary_doc.xml · nonDerivative · entry 2 Poukalov Konstantin · CIK 0001678736 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Read SEC document |
| November 11, 2016 Filed Nov 14, 2016 08:41 UTC | Kadmon Holdings, Inc. kdmn · Entity 133686 | PurchaseCommon stock, par value $0.001 | 1,000 | $5.96 | $5,960.00 |
DisclosureSEC source: 0001557142-16-000040 · primary_doc.xml · nonDerivative · entry 1 Poukalov Konstantin · CIK 0001678736 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.